Hoffmann-la Roche Inc.

Roche Colorado Corporation

Genentech, Inc.

Roche Palo Alto LLC

Roche Vitamins Inc.

Array Biopharma Inc.

Dsm IP Assets B.v.

F. Hoffmann-la Roche Ag

Peter Vogt

Michelangelo Scalone

Kurt Puentener

Ulrich Zutter

Reinhard Reents

Lewis M Hodges

Thomas Albert Zeibig

Francis Gosselin

Hans Iding

Yeun-Kwei Han

Michael P Fleming

Shaoning Wang

David A Johnston

Robert J Topping

Mark A Schwindt

Roger P Micheli

Chris R Roberts

Yvo Crameri

Bernd Junghans

Peter Karl Matzinger

Andreas Zogg

Kurt P&uuml;ntener

Milan R Uskokovic

Beat Wirz

Urs Schwitter

Stefan Hildbrand

Olaf Grassmann

Hans-Juergen Mair

John A McLane

Masami Okabe

Helmut Werner Stahr

Thomas I Doran

Bernd Kuhn

Peter Mohr

Patrizio Mattei

Andrew William Thomas

Patrick Schnider

Johannes Aebi

Rainer Eugen Martin

Philippe Pflieger

Ralf Karch

Angelino Doppiu

Hans Peter Maerki

Holger Kuehne

Eileen Woerner

Thomas Luebbers

Benoit Hornsperger

Andreas Rivas-Nass

Rene Wyler

Kurt E Amrein

Christof Wehrli

Rosa Maria Rodriguez Sarmiento

Rudolf Schmid

Xuefei Tan

Emil A Broger

Lawrence Emerson Fisher

Matthias Beller

Keith Lee Spencer

Yongfu Liu

Ulrich Widmer

Mingwei Zhou

Peter J Stengel

Paul Spurr

Stephan Bachmann

Peter John Harrington

Weidong Liu

Paul Nichols

Sagar Raj Shakya

Pius Waldmeier

Chong Han

Bruno Lohri

Andrea Cesura

Fabienne Hoffmann-Emery

Ursula Hoffmann

Roland Winde

Roland Meier

Justin Philip Vitale

Serena Maria Fantasia

Cyrille Maugeais

Alexander V Mayweg

Stefan Abrecht

Franziska E Rohrer

Ernst Kupfer

Francois Montavon

Kathrin Junge

Regina Moog

Andre Bubendorf

Paul J Nichols

Andreas Knierzinger

Armin Ruf

Joachim Veits

Stephan Goetzoe

Kazimierz Michal Pietrusiewicz

Wolfgang Goehring

Kieran Durkin

Zackary D Crane

Dennis Smith

Andreas Staempfli

Christian Walch

Andrew Walsh

The invention comprises novel chiral metal complex compounds of the formula  wherein M, PR, Rand Rare outlined in the description, its stereoisomers, in the form as a neutral complex or a complex cation with a suitable counter ion. The chiral metal complex compounds can be used in asymmetric reactions, particularly in asymmetric reductions of ketones, imines or oximes.

Chiral metal complex compounds

The present invention relates to a process for the preparation of a compound of formula (I) 

Processes for the preparation of pyrimidinylcyclopentane compounds

The invention provides processes of preparation thereof useful in the preparation of compounds that can be used as CHK1 inhibitors.

Process for preparing a compound

The present invention relates to a process for the preparation of a compound of formula (I), wherein Ris as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds. 

The present invention relates to a process for the preparation of S-[2-[1-(2 -ethylbutyl)cyclohexylcarbonylamino]-phenyl] 2-methylthiopropionate which is useful as a pharmaceutically active compound.

Process

The present invention provides processes to manufacture crystalline N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide. Also disclosed are compounds useful as intermediates in the methods of the invention.

Process to manufacture N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxo-pyrrolidin-3-yl]acetamide

The invention provides novel compounds having the general formula (I) wherein R, R, R, R, R, R, R, R, R, R, R, R, A, AAand n are as described herein, compositions including the compounds and methods of using the compounds. The compounds of the present invention are useful as inhibitors of aldosterone synthase. The compounds may be used, for example, in the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

Bicyclic dihydroquinoline-2-one derivatives

A process for the preparation of a compound of formula (I): which is useful as an intermediate in the preparation of pharmaceutically active compounds.

Process for the preparation of cyclohexanecarboxylic acid derivatives

The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is useful as a pharmaceutically active compound.

The invention relates to a process for the preparation of a compound of formula (I) or a salt thereof.

Process for the preparation of propionic acid derivatives

The invention relates to a novel process for the preparation of Ruthenium metathesis catalysts of the formula  Ruthenium metathesis catalysts have been widely applied in the synthesis of macrocyclic drug compounds.

Process for the preparation a ruthenium complex

The present invention relates to a new process for the preparation of macrocyclic HCV protease inhibitor compounds of the formula wherein Ris an amino protecting group and X is halogen by way of a ring closing metathesis approach.

Process for the preparation of a macrocycle

The invention relates to novel metathesis catalysts of the formula a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis. The invention further relates to a process for the manufacture of a macrocyclic compound of formula VII which have the potential to be useful as HCV protease inhibitors.

Ruthenium complexes as catalysts for metathesis reactions

Growing community of inventors

Birsfelden, Switzerland

Michelangelo Scalone